JOHN SEYMOUR (MELBOURNE)
VENETOCLAX
The reported mechanisms of venetoclax resistance in CLL in the clinical setting will be reviewed
and discussed with an emphasis on the major role for the spectrum of acquired BCL2 mutations
interfering with venetoclax binding, as well as other adaptive changes in other elements of the
apoptotic regulatory pathways.
References:
a. Blombery et al. Cancer Discovery 9:342-53, 2019
b. Blombery et al Blood 135:773-7, 2020
c. Guieze R et al Cancer Cell 36:369-84, 2019
